Therapeutic targeting of the pro-tumoral IL-25-ILC2 axis via antibody-mediated blockade reduced intratumoral M-MDSCs and enhanced adaptive T cell IFNγ expression, leading to reduced CRC burden in mice. This evidence concerns the gene IFNG and colorectal carcinoma.